-+ 0.00%
-+ 0.00%
-+ 0.00%

COCRYSTAL PHARMA ANNOUNCES LAST SUBJECT DOSED IN PHASE 1B HUMAN CHALLENGE STUDY EVALUATING CDI-988 FOR NOROVIRUS PREVENTION AND TREATMENT

Reuters·09/09/2026 11:00:00

Please log in to view news